Who
Gordon Carmichael
Director
Company insider
Files Form 4 as: Director, Gyre Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 Oct 2023
- Last trade
- 10 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 30 Jun 2026 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 10 Jun 2026filed 30 Jun 2026 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 14 Aug 2024filed 16 Aug 2024 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 31 Oct 2023filed 1 Nov 2023 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,866 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.